TrialCancer communications (London, England)2021

Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

Wu-Tong Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.